At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 305 enrolled
Drug / intervention
Tezepelumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants With Severe Asthma on High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)
In Brief
A Phase 3 clinical trial evaluating Tezepelumab for Asthma. Completed, enrolled 305 participants across 77 sites in 11 countries.
Detailed Summary
This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Belgium, Bulgaria, France, Germany, Latvia, Mexico, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMay 2022
Primary CompletionSep 2024
TodayJul 2026
First PostedMar 10, 2022
Enrollment StartMay 17, 2022
Primary CompletionSep 9, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.3 years ago
Interventions
Tezepelumabbiological
Tezepelumab subcutaneous injection